Not logged in.png)
Share.png)
SaveShare Save Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer
Sheng, Xinan; Zeng, Gongqian; Zhang, Cuijian; Zhang, Qingyun; Bian, Jiasheng; Niu, Haitao; Li, Jun; Shi, Yanxia; Yao, Kai; Hu, Bin; Liu, Ziling; Liao, Hong; Yu, Zhixian; Jin, Baiye; Zhao, Peng; Yang, Tiejun; Liu, Xianling; Qin, Yang; Xue, Xueyi; Gou, Xin; Huang, Jian; Gu, Jiang; Qi, Xiaolong; Zhang, Lu; Ma, Guoxian; Liu, Beisong; Fang, Jianmin; Jiang, Shusuan; He, Zhisong; Zhou, Aiping; Guo, Jun Share Save Share Save Prognostic index for predicting outcomes of trastuzumab deruxtecan in HER2 expressing metastatic breast cancer: a real-world multicenter studyXue, Cong; Liao, Qianyi; Huang, Riqing; Huang, Yunjie; Chen, Rishang; Yang, Zhenhua; Shen, Xiujiao; Li, Haifeng; Rong, Qixiang; Shu, Ditian; Pan, Fei; Shi, Yanxia; Chen, Meiting Share Save Share Save Olanzapine combined with standard antiemetics for the prevention of nausea and vomiting in patients with germ cell tumor undergoing a 5-day cisplatin-based chemotherapy (NAVIGATE study): A phase III crossover trialZhang, Lulu; Chen, Meiting; Zhou, Qingru; Xue, Cong; Huang, Riqing; Diao, Xiaoju; Li, Jibin; Peng, Jing; Zheng, Qiufang; Ni, Mengqian; Zhou, Lijia; Wang, Daining; Li, Haifeng; Yang, Wei; Dun, Shu; Liu, Zhuowei; Wang, Yalan; Shi, Yanxia; An, Xin Share Save Bevacizumab, tislelizumab and nab-paclitaxel for previously untreated metastatic triple-negative breast cancer: a phase II trialChen, Meiting; Huang, Riqing; Rong, Qixiang; Yang, Wei; Shen, Xiujiao; Sun, Qi; Shu, Ditian; Jiang, Kuikui; Xue, Cong; Peng, Jing; An, Xin; Li, Haifeng; Xu, Fei; Shi, Yanxia Share Save CYP2D6 polymorphisms and endoxifen concentration in Chinese patients with breast cancerXue, Cong; Yang, Wei; Hu, Anqi; He, Caiyun; Liao, Hai; Chen, Meiting; An, Xin; Wang, Shusen; Yuan, Zhongyu; Xu, Fei; Tang, Jun; Li, Haifeng; Li, Su; Shao, Jianyong; Shi, Yanxia Share Save Impacts of genomic alterations on the efficacy of HER2-targeted antibody-drug conjugates in patients with metastatic breast cancerHuang, Riqing; Hu, Anqi; Rong, Qixiang; Shu, Ditian; Chen, Meiting; Yang, Wei; Zhang, Yue; Zheng, Qiufan; An, Xin; Xue, Cong; Li, Haifeng; Shi, Yanxia Share Save Clinical outcome and prognostic factors for immunotherapy-based treatments in patients with platinum-refractory germ cell tumorHuang, Riqing; Shu, Ditian; Li, Haifeng; Hu, Anqi; Chen, Meiting; Yang, Wei; Zhang, Yue; Zheng, Qiufan; An, Xin; Xue, Cong; Shi, Yanxia Share Save Screening optimal candidates with operable, early-stage triple-negative breast cancer benefitting from capecitabine maintenance: A post-hoc analysis of the SYSUCC-001 studyDuan, Fangfang; Hua, Xin; Bi, Xiwen; Wang, Shusen; Shi, Yanxia; Xu, Fei; Wang, Li; Huang, Jiajia; Yuan, Zhongyu; Huang, Yuanyuan Share Save Pyrotinib and trastuzumab plus palbociclib and fulvestrant in HR+/HER2+ breast cancer patients with brain metastasisChen, Dongshao; Xu, Fei; Lu, Yongkui; Xia, Wen; Du, Caiwen; Xiong, Dun; Song, Dong; Shi, Yanxia; Yuan, Zhongyu; Zheng, Qiufan; Jiang, Kuikui; An, Xin; Xue, Cong; Huang, Jiajia; Bi, Xiwen; Chen, Meiting; Zhang, Jingmin; Wang, Shusen; Hong, Ruoxi Share Save Does the Dose of Standard Adjuvant Chemotherapy Affect the Triple-negative Breast Cancer Benefit from Extended Capecitabine Metronomic Therapy? An Exploratory Analysis of the SYSUCC-001 TrialChen, Ying; Li, Wen-Xia; Wu, Jia-Hua; Chen, Geng-Hang; Yang, Chun-Min; Lu, Hai; Wang, Xi; Wang, Shu-Sen; Huang, Heng; Cai, Li; Zhao, Li; Peng, Rou-Jun; Lin, Ying; Tang, Jun; Zeng, Jian; Zhang, Le-Hong; Ke, Yong-Li; Wang, Xian-Ming; Liu, Xin-Mei; Zhang, An-Qin; Xu, Fei; Bi, Xi-Wen; Huang, Jia-Jia; Li, Ji-Bin; Pang, Dan-Mei; Xue, Cong; Shi, Yan-Xia; He, Zhen-Yu; Lin, Huan-Xin; An, Xin; Xia, Wen; Cao, Ye; Guo, Ying; Hong, Ruo-Xi; Jiang, Kui-Kui; Zhong, Yong-Yi; Zhang, Ge; Tienchaiananda, Piyawan; Oikawa, Masahiro; Yuan, Zhong-Yu; Chen, Qian-Jun Share Save A real-world observation on thrombopoietic agents for patients with cancer treatment-induced thrombocytopenia in China: A multicenter, cross-sectional studyChen, Meiting; Li, Lu; Xia, Qing; Chen, Xiaobing; Liao, Zijun; Wang, Chang; Shen, Bo; Zhou, Min; Zhang, Qingyuan; Zhang, Yanqiao; Qian, Liting; Yuan, Xianglin; Wang, Zhehai; Xue, Cong; An, Xin; Liu, Bin; Gu, Kangsheng; Hou, Mei; Wang, Xiaojia; Wang, Wei; Li, Enxiao; Zhong, Jincai; Cheng, Jing; Shu, Yongqian; Yang, Nong; Wang, Huaqing; Yang, Runxiang; Liu, Tianshu; Deng, Ting; Ma, Fei; Liao, Wangjun; Qiu, Wensheng; Chen, Yu; Chen, Xi; Zhang, Mingzhi; Xu, Ruilian; Li, Xiaoling; Feng, Jifeng; Ba, Yi; Shi, Yanxia Share Save Gemcitabine/nab-paclitaxel vs gemcitabine/carboplatin for advanced urothelial carcinomaAn, Xin; Xue, Cong; Chen, Meiting; Ni, Mengqian; Ma, Huali; Tian, Li; Huang, Riqing; Li, Xiangdong; Ye, Yunlin; Qin, Tao; Dong, Pei; Li, Zhiyong; Peng, Jing; Yao, Kai; Zhou, Fangjian; Liu, Zhuowei; Shi, Yanxia Share Save Pyrotinib plus docetaxel as first-line treatment for HER2-positive metastatic breast cancer: the PANDORA phase II trialZheng, Yabing; Cao, Wen-Ming; Shao, Xiying; Shi, Yanxia; Cai, Li; Chen, Wenyan; Liu, Jian; Shen, Peng; Chen, Yiding; Wang, Xian; Li, Huiping; Li, Man; Chen, Zhanhong; Wang, Xiaojia Share Save Effect of chemotherapy alone or combined with immunotherapy for locally advanced or metastatic genitourinary small cell carcinoma: a real-world retrospective studyHuang, Riqing; Chen, Meiting; Li, Haifeng; An, Xin; Xue, Cong; Hu, Anqi; Shu, Ditian; Yang, Wei; Zhou, Fangjian; Sui, Dan; Yao, Kai; Li, Yonghong; Wu, Zhiming; Li, Zhiyong; Liu, Zhuowei; Shi, Yanxia Share Save Assessment of the expression pattern of HER2 and its correlation with HER2-targeting antibody-drug conjugate therapy in urothelial cancerLei, Huizi; Ling, Yun; Yuan, Pei; Yan, Xieqiao; Wang, Lin; Shi, Yanxia; Yao, Xin; Luo, Hong; Shi, Benkang; Liu, Jiyan; He, Zhisong; Yu, Guohua; Han, Weiqing; Hu, Changlu; Chi, Zhihong; Cui, Chuanliang; Si, Lu; Fang, Jianmin; Guo, Jun; Sheng, Xinan; Zhou, Aiping; Ying, Jianming Share Save Phase I study of LZM005 in patients with HER2-positive metastatic breast cancerXue, Cong; Li, Haifeng; Yao, Herui; Lin, Ying; An, Xin; Chen, Meiting; Huang, Riqing; Li, Lu; Hu, Anqi; Ni, Mengqian; Zhang, Lulu; Yang, Wei; Xu, Zhonghui; Li, Su; Shi, Yanxia Share Save 
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
